This study is a prospective, single-arm, multicenter trial designed to evaluate the hematologic response rate and safety of GPRC5D/CD3 bispecific antibody bridging therapy prior to CAR-T cell infusion in patients with relapsed/refractory multiple myeloma (RRMM).
Voluntary Participation: Ability to understand and voluntarily sign the informed consent form (ICF).
Age ≥18 years.
Confirmed symptomatic MM diagnosis per the Chinese Guidelines for Diagnosis and Management of Multiple Myeloma (2022 Revision).
Successful apheresis for CAR-T cell manufacturing.
Prior GPRC5D-targeted immunotherapy.
Investigator-assessed contraindications to GPRC5D×CD3 bispecific antibody therapy (e.g., severe cardiopulmonary diseases incompatible with treatment).
Grade >2 peripheral neuropathy or ≥grade 2 painful neuropathy at screening (regardless of current medication).
Known intolerance, hypersensitivity, or contraindication to GPRC5D×CD3 bispecific antibody components.